FIGURE 3-1 Global TB drug pipeline, as of June 18, 2012.

NOTE: GLP, Good Laboratory Practices; Tox., toxicity.

a Ongoing projects without a lead compound series can be viewed at (accessed November 19, 2012).

b Combination regimens: first clinical trial (NC001) of a novel TB drug regimen testing the three drug combination of PA-824, moxifloxacin, and pyrazinamide was initiated November 2010 and completed in 2011 with promising results. The second clinical trial (NC002) of this regimen was launched in March 2012 and will test the efficacy of the regimen in drug-sensitive and multidrug-resistant patients. The third clinical trial (NC003) will evaluate PA-824, TMC-207, pyrazinamide, and clofazimine in combinations and is scheduled to begin September 2012.

SOURCE: Kimerling, 2012. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement